Impel NeuroPharma

72 articles with Impel NeuroPharma

• Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25

  4/21/2022

  Impel NeuroPharma announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022.

• Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference

  4/7/2022

  Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022 at 1:30 p.m. ET.

• Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/24/2022

  Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the fourth quarter and full year ended December 31, 2021, and a corporate update.

• Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology

  3/22/2022

  Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced planned poster presentations at the upcoming American Academy of Neurology (AAN) annual meeting.

• Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

  3/17/2022

  Impel NeuroPharma (NASDAQ: IMPL), today announced it will host a live webcast on Thursday, March 24, 2022, at 8:30 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update.

• Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree

  3/17/2022

  Impel NeuroPharma announced two separate transactions with funds managed by Oaktree Capital Management, L.P. totaling $100 million in gross funding.

• Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

  2/28/2022

  Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

• Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

  1/18/2022

  Impel NeuroPharma today provided updates on Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) launch progress and recent business highlights.

• Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

  11/15/2021

  Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference

  11/9/2021

  Impel NeuroPharma, Inc. today announced that Adrian Adams, Chairman and CEO, will participate in a fireside chat at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference on Tuesday, November 16, 2021 at 1:40 p.m. ET.

• Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

  11/8/2021

  Impel NeuroPharma, Inc. (NASDAQ: IMPL), today announced that management will host a live webcast on Monday, November 15, 2021 at 8:30 a.m. ET to report its third quarter 2021 financial results and provide a business update.

• Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine

  9/28/2021

  Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that Trudhesa™ nasal spray is now available for prescription.

• Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering

  9/10/2021

  Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $15.00 per share.

• Impel NeuroPharma Announces Launch of Proposed Public Offering - Sep 07, 2021

  9/7/2021

  Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock.

• 

  FDA Action Alert: Impel and Merck

  9/6/2021

  Sometimes the U.S. Food and Drug Administration (FDA) runs ahead of schedule. In the case of this week’s two PDUFA dates, that was completely true. Here’s a look.

• Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine

  9/3/2021

  Impel NeuroPharma, Inc. (NASDAQ: IMPL), today announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults.

• Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

  8/16/2021

  Impel NeuroPharma today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• 

  Clinical Catch-Up: August 9-13

  8/16/2021

  There was plenty of clinical trial updates last week. Here’s a look.

• Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

  8/9/2021

  Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced it will host a live webcast on Monday, August 16, 2021 at 8:30 a.m. ET to report its second quarter 2021 financial results and provide a business update.

• Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache

  8/9/2021

  Impel NeuroPharma (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases who have high unmet medical needs, announced today that its pivotal Phase 3, open-label study, STOP 301, was published in the August 7, 2021 edition of Headache: The Journal of Head and Face Pain, the official journal of the American Headache Society.